Galectin Therapeutics's total assets for Q2 2025 were $15.60M, an increase of 63.75% from the previous quarter. GALT total liabilities were $132.77M for the fiscal quarter, a 9.02% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.